GLAXF News and Press, GlaxoSmithKline Plc From 02/18/20

Source: Barron's Gilead ( GILD ) reported a Q4 revenue of $5.88 billion, Non-GAAP EPS of $1.30 and GAAP EPS of $2.12. The stock is flat post-earnings. I have been bearish on Gilead for a few years now. The company's top line has gone through fits and starts and it will likely continue th...

Veeva ( VEEV ) has been a leader of cloud-based compliance and software solutions for the growing life sciences industry. The business is comprised of two segments: Veeva Commercial Cloud and Veeva Vault. Commercial Cloud is Veeva's flagship product and provides features to customers, inc...

This article is part of a series that provides an ongoing analysis of the changes made to Kenneth Fisher’s 13F stock portfolio on a quarterly basis. It is based on Fisher Asset Management’s regulatory 13F Form filed on 02/12/2020. Please visit our Tracking Kenneth Fisher's Fis...

Musings January 2020 was a tough month for stocks but was especially tough for value and international (especially emerging markets). Source: S&P Dow Jones Source: S&P Dow Jones I hate to dwell on the ugly, but things were really ugly for domestic energy stocks as w...

GlaxoSmithKline plc (GSK) Q4 2019 Results Earnings Conference Call February 05, 2020, 9:00 am ET Company Participants Sarah Elton-Farr - Head of Global Investor Relations Emma Walmsley - Chief Executive Officer Iain Mackay - Chief Financial Officer Hal Barron - Chief Scientific...

The following slide deck was published by GlaxoSmithKline plc in conjunction with their 2019 Q4 earnings Read more ...

Source (Shutterstock/Liya Graphics) Introduction Gilead Sciences ( GILD ) was positioned to be the poster child of Trump's plan to eradicate HIV, as outlined in my previous article . Like almost all outbreaks including the Wuhan coronavirus, the only effective way to complete...

Quick Take Aditx Therapeutics ( ADTX ) has filed to raise $10.5 million in an IPO of its common stock and warrants, according to an S-1 registration statement . The company is a pre-clinical developer of immune suppression drugs to assist in organ transplantation procedures. ADTX is sti...

Actionable Conclusions (1-5): Brokers Predicted 26.35% To 53.85% Net Gains From Top Five Healthcare Sector Dogs By April 2020 One of five top dividend-yielding Healthcare dogs was verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (...

New York-based pharma giant Pfizer (NYSE: PFE) sold US$5bn of new corporate bonds Monday in five parts, as the company contributes to a groundswell of issuance amid low U.S. interest rates. The senior unsecured deal, comprised of maturities ranging from two- to 30-years, attracted decent dem...